NE-AAV Vectors for Sustained Liver Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional liver-directed AAV gene therapies are ineffective in children due to liver growth and division diluting AAV vector genomes and the development of pre-existing antibodies, making repeat dosing challenging for treating liver diseases like hemophilia.
Innovation Solution
Development of no-end adeno-associated virus (NE-AAV) DNA genomes with truncated and modified recombinant AAV inverted terminal repeats (ITRs) that increase stability and transgene expression, allowing for effective delivery of therapeutic genes to children's livers without inducing an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional AAV vectors are used for gene therapy in children, then initial transgene expression can be achieved, but the vector genomes are diluted out due to liver cell division and pre-existing antibodies prevent repeat dosing
Solution Approach 1:
The patent modifies the ITR structure by truncating it to a specific length (e.g., 47 nucleotides) and altering its sequence composition to create a novel parameter state. This truncated ITR configuration changes how the vector genome interacts with host cell machinery, enabling integration or persistent maintenance that withstands liver cell division, thereby resolving the contradiction between initial expression and long-term persistence.
Solution Approach 2:
The patent creates a simplified copy or derivative of the natural ITR structure (truncated version) that retains essential functions while removing problematic elements. This copied structure is then used to generate new vector genomes that can persist through cell division, solving the durability issue without requiring the full-length original ITR.
2Reliability
If repeat dosing is attempted with traditional AAV vectors, then therapeutic levels might be maintained, but pre-existing antibodies block subsequent administrations
Solution Approach 1:
The patent extracts or removes the full-length ITR structure that triggers immune recognition, replacing it with a truncated version that maintains therapeutic function but reduces immunogenicity. This extraction of the problematic full-length structure allows repeat dosing to proceed without antibody interference, resolving the contradiction between maintaining therapy and avoiding immune response.
3Stability of the object's composition
If full-length AAV ITRs are used, then vector stability is maintained, but transgene expression longevity is limited due to episomal nature and cell division
Solution Approach 1:
The patent changes the structural parameter of the ITR from full-length to truncated configuration, fundamentally altering how the vector genome behaves in host cells. This parameter change enables the genome to either integrate into host DNA or adopt a persistent maintenance mechanism that survives liver cell division, simultaneously achieving stability and long-term expression longevity.
Data Source
AI summary
The present invention provides optimized no-end adeno-associated virus (NE-AAV) DNA genomes comprising recombinant AAV inverted terminal repeats (ITRs), compositions comprising the same, and methods of use thereof to treat certain diseases or disorders. Such genomes and compositions may be useful in the delivery of therapeutic genes to subjects in need thereof, for example in the treatment of certain diseases or disorders known to be associated with the liver, such as hemophilia. The methods of the disclosure may be useful in the site-specific integration of NE-DNA and treatment of hemophilia in humans, including children.